NEWAVE PHARMACEUTICAL INC.
🇺🇸United States
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1
Recruiting
- Conditions
- Hairy Cell LeukemiaWaldenstrom MacroglobulinemiaCLL/SLLMantle Cell LymphomaMarginal Zone LymphomaFollicular LymphomaDiffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Newave Pharmaceutical Inc
- Target Recruit Count
- 60
- Registration Number
- NCT04775745
- Locations
- 🇺🇸
Duke Univerisity, Durham, North Carolina, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1
Recruiting
- Conditions
- Richter TransformationT-cell-prolymphocytic LeukemiaMyelodysplastic/Myeloproliferative NeoplasmSmall Lymphocytic LymphomaMyelodysplastic Neoplasm in Blast PhaseNon Hodgkin LymphomaMultiple MyelomaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaMyeodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Newave Pharmaceutical Inc
- Target Recruit Count
- 100
- Registration Number
- NCT04771572
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Phase 1
Active, not recruiting
- Conditions
- AML/MDSCMMLRelapseRefractory Acute Lymphoblastic LeukemiaRelapse LeukemiaRelapsed Adult AML
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Newave Pharmaceutical Inc
- Target Recruit Count
- 36
- Registration Number
- NCT04139434
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Ohio State Comprehensive Cancer Center, Columbus, Ohio, United States
News
No news found